Accuray has received CE Mark for its Accuray Helix CT-guided helical radiotherapy system, designed specifically for emerging markets like India that have limited access to advanced cancer treatments.

"Our initial focus is on expanding patient access to radiation therapy treatments in emerging markets where access to advanced cancer care, including radiotherapy, is typically obtainable only within urban areas and where the availability of linear accelerators per million population is well below the World Health Organization recommended guidelines," Suzanne Winter, president and CEO of Accuray, told HCB News.

The Accuray Helix is geared toward facilities that only have the resources and staff to operate one radiation therapy system, and is equipped with automation tools that speed up the planning and treatment delivery process.

"[It's] composed of the components necessary for enabling precision, versatility and short treatment times while also being easy to use," Winter explained. "The Helix broadens our portfolio of products, so that we can offer customers many system options depending on their budget and need for advanced capabilities driven by patient mix."

Even though it’s a more affordable option, the system is an advanced radiation therapy system capable of treating breast, cervix, head and neck, gastrointestinal, lung, and prostate cancer.

Accuray received approval from the Chinese National Medical Products Administration in June for its Accuray Precision Treatment Planning System. It’s intended to be used with the CNNC-Accuray joint venture Tomo C radiation therapy system.

According to the company, this provides China with a new option to deliver “extremely precise and accurate” radiotherapy treatments, with the ultimate goal of expanding access to this type of care to more patients within the country.

Rad Oncology Homepage